{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:07:19Z","timestamp":1790014039296,"version":"4.0.1"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"Importance<\/jats:title>Patients with psoriasis may require a switch to another therapy due to high treatment costs, primary effectiveness failure, biologic fatigue, or adverse effects associated with the initial biologic treatment; however, the availability of evidence for the effectiveness and safety of interclass biologic switching for the treatment of psoriasis is unknown.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate the effectiveness and safety of psoriasis treatment after the failure of initial biologic therapy, particularly when patients switch to a second biologic.<\/jats:p><\/jats:sec>Data Sources<\/jats:title>PubMed, Embase, and the Cochrane Library were searched from inception through January 25, 2025.<\/jats:p><\/jats:sec>Study Selection<\/jats:title>The study included randomized clinical trials (RCTs) of patients with plaque psoriasis aged 18 years or older involving crossover or switching from 1 biologic agent to another initial biologic within the same or different drug class.<\/jats:p><\/jats:sec>Data Extraction and Synthesis<\/jats:title>Two researchers independently screened the records and abstracted data using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline. Data were pooled using random-effects models.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The prespecified primary end point was psoriasis area and severity index (PASI) 90. Secondary end points included clinician- and patient-reported outcomes (PROMs) and safety. Clinical effectiveness was evaluated based on the PASI responses (PASI 75, 90, and 100) and the Investigator\u2019s and Physician\u2019s Global Assessments scores of 0 or 1 and body surface area of 1% or less. PROMs included the dermatology life quality index and psoriasis symptoms and signs diary. Safety concerns included adverse events (AEs), serious AEs, severe AEs, treatment-related AEs, and specific AEs.<\/jats:p><\/jats:sec>Results<\/jats:title>Twenty-four RCTs involving 12\u202f661 patients with psoriasis and 8 switching categories were analyzed. Significant differences observed in PASI 90 between week 4 and week 0 (odds ratio [OR], 6.53; 95% CI, 2.58-16.51). Substantial disparities were noted across various PASI response metrics, specifically PASI 90 (OR, 28.61; 95% CI, 12.89-63.47), PASI 75 (OR, 11.11; 95% CI, 5.95-20.75), and PASI 100 (OR, 18.76; 95% CI, 8.37-42.01). No difference exists in safety outcomes between the end point and week 0, including in serious AEs (OR, 1.63; 95% CI, 0.72-3.69), severe AEs (OR, 1.40; 95% CI, 0.61-3.26), and treatment-related AEs (OR, 1.79; 95% CI, 0.41-7.88). The highest risk of infection was associated with switching from anti\u2212TNF-\u03b1 agents to anti\u2212interleukin (IL)-23p19, anti\u2212IL-17A, or anti\u2212IL-12\/23p40 agents, with infection rates of 0.62%, 0.54% and 0.39%, respectively.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This systematic review and meta-analysis found that interclass biologic switching was effective in a significant number of patients. With the introduction of biologics with diverse mechanisms of action, these options may become viable and potentially superior. However, further confirmatory data from larger patient cohorts and longer follow-up periods are required to obtain more conclusive results. Our results highlight the importance of vigilance for infections when switching biologics.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.2714","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T15:00:39Z","timestamp":1754492439000},"page":"1029","source":"Crossref","is-referenced-by-count":13,"title":["Biopharmaceutical Switching in Psoriasis Treatment"],"prefix":"10.1001","volume":"161","author":[{"given":"Miao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seokgyeong","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyun","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Sun","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqiong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Luo","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naixuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juntang","family":"Yan","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"doi250038r1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd1607","article-title":"Psoriasis: emerging therapeutic strategies.","volume":"4","author":"Gottlieb","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"doi250038r2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/17512433.2020.1767590","article-title":"Switching biologics in psoriasis - practical guidance and evidence to support.","volume":"13","author":"Tsai","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"doi250038r3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3109\/09546634.2013.826341","article-title":"Biologic fatigue in psoriasis.","volume":"25","author":"Levin","year":"2014","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"doi250038r4","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1046\/j.1365-2230.2001.00829.x","article-title":"Therapeutic strategies: rotational therapy and combinations.","volume":"26","author":"van de Kerkhof","year":"2001","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"doi250038r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103530","article-title":"Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: an analysis of current evidence.","volume":"23","author":"Sun","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"4","key":"doi250038r6","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi250038r7","doi-asserted-by":"publisher","first-page":"13699","DOI":"10.1038\/s41598-023-40222-5","article-title":"Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis.","volume":"13","author":"de Oliveira Ascef","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"doi250038r8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","article-title":"Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.","volume":"77","author":"Kay","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"doi250038r9","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jaad.2016.02.1221","article-title":"Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent.","volume":"75","author":"Yamauchi","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi250038r10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jaad.2020.11.022","article-title":"Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial.","volume":"85","author":"Blauvelt","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi250038r11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"doi250038r12","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3109\/09546634.2015.1114567","article-title":"Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary.","volume":"27","author":"Mathias","year":"2016","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"doi250038r13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/bjd\/ljac021","article-title":"Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.","volume":"188","author":"Tha\u00e7i","year":"2023","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi250038r14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis.","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"doi250038r15","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2023.04.063","article-title":"Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.","volume":"89","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi250038r16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi250038r17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/bjd\/ljac089","article-title":"Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III\/IIIb trials.","volume":"188","author":"Kokolakis","year":"2023","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi250038r18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/bjd.17454","article-title":"Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.","volume":"180","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi250038r19","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jaad.2021.11.004","article-title":"Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi250038r20","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jaad.2018.05.032","article-title":"Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study.","volume":"79","author":"Leonardi","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi250038r21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/jdv.15921","article-title":"Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.","volume":"34","author":"Lebwohl","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10198","key":"doi250038r22","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"doi250038r23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bjd.19866","article-title":"Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).","volume":"185","author":"Thaci","year":"2021","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi250038r25","first-page":"163","article-title":"Diagnosis and management of common tinea infections.","volume":"58","author":"Noble","year":"1998","journal-title":"Am Fam Physician"},{"issue":"12","key":"doi250038r26","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1080\/17476348.2021.1988569","article-title":"Management of acute upper respiratory tract infection: the role of early intervention.","volume":"15","author":"Wang","year":"2021","journal-title":"Expert Rev Respir Med"},{"issue":"2","key":"doi250038r27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1164\/rccm.202011-4239PP","article-title":"Latent tuberculosis: two centuries of confusion.","volume":"204","author":"Behr","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"doi250038r28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrurol.2010.190","article-title":"The epidemiology of urinary tract infection.","volume":"7","author":"Foxman","year":"2010","journal-title":"Nat Rev Urol"},{"issue":"4","key":"doi250038r29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.crohns.2012.06.024","article-title":"The complexity of adverse side-effects to biological agents.","volume":"7","author":"Aubin","year":"2013","journal-title":"J Crohns Colitis"},{"issue":"2","key":"doi250038r30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/bjd.17318","article-title":"Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.","volume":"180","author":"Langley","year":"2019","journal-title":"Br J Dermatol"},{"issue":"8","key":"doi250038r31","first-page":"826","article-title":"Long-term efficacy of guselkumab for the treatment of moderate-to-severe psoriasis: results from the phase 3 VOYAGE 1 trial through two years.","volume":"17","author":"Griffiths","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"doi250038r32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40257-016-0246-9","article-title":"Efficacy and safety of switching to ixekizumab in etanercept non-responders: a subanalysis from two phase III randomized clinical trials in moderate-to-severe plaque psoriasis (UNCOVER-2 and -3).","volume":"18","author":"Blauvelt","year":"2017","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"doi250038r33","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/bjd.18484","article-title":"Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.","volume":"182","author":"Kimball","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi250038r34","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ad.2017.02.005","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study.","volume":"108","author":"Valenzuela","year":"2017","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"doi250038r35","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.jaad.2017.06.153","article-title":"Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).","volume":"77","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi250038r36","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1080\/09546634.2020.1782817","article-title":"Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1.","volume":"33","author":"Griffiths","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"doi250038r37","doi-asserted-by":"publisher","first-page":"AB55","DOI":"10.1016\/j.jaad.2019.06.232","article-title":"Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis.","volume":"81","author":"Ryan","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi250038r38","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi250038r39","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"doi250038r40","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s40257-020-00555-7","article-title":"Maintenance of response through up to 4 years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 study.","volume":"21","author":"Reich","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"doi250038r41","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjd.20568","article-title":"Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.","volume":"185","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"key":"doi250038r42","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.41053","article-title":"Patients with persistent mild psoriasis after treatment with ustekinumab achieved greater improvements in skin clearance and patient-reported outcomes after switching to guselkumab in the phase 3 NAVIGATE Trial.","volume":"104","author":"Errichetti","year":"2024","journal-title":"Acta Derm Venereol"},{"key":"doi250038r43","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2442603","article-title":"Risk of Candida infection and serious infections in patients with moderate-to-severe psoriasis receiving biologics: a systematic review and meta-analysis of randomized controlled trials.","volume":"2022","author":"Feng","year":"2022","journal-title":"Int J Clin Pract"},{"issue":"5","key":"doi250038r44","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.chom.2012.04.008","article-title":"Th17 cells in immunity to Candida albicans.","volume":"11","author":"Hern\u00e1ndez-Santos","year":"2012","journal-title":"Cell Host Microbe"},{"issue":"3","key":"doi250038r45","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3386","article-title":"Psoriasis and treatment: past, present and future aspects.","volume":"100","author":"Reid","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"doi250038r46","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ad.2015.04.013","article-title":"Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time.","volume":"106","author":"Carrascosa","year":"2015","journal-title":"Actas Dermosifiliogr"},{"issue":"7","key":"doi250038r47","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/jamadermatol.2023.1338","article-title":"Biosimilars for the treatment of psoriasis: a systematic review of clinical trials and observational studies.","volume":"159","author":"Phan","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"3","key":"doi250038r48","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40261-017-0603-3","article-title":"A review of switching biologic agents in the treatment of moderate-to-severe plaque psoriasis.","volume":"38","author":"Hu","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"3","key":"doi250038r49","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jaci.2023.03.035","article-title":"Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease.","volume":"152","author":"Cole","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"doi250038r50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1191782","article-title":"The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases.","volume":"14","author":"Navarro-Comp\u00e1n","year":"2023","journal-title":"Front Immunol"},{"key":"doi250038r24","volume-title":"Oral Candidiasis. StatPearls. StatPearls Publishing","author":"Taylor","year":"2025"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2837167\/jamadermatology_zhang_2025_oi_250038_1760475172.18406.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:02:25Z","timestamp":1760540545000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2837167"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.2714","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}